• In late February 2026, AdaptHealth Corp. reported full-year 2025 results showing net revenue of US$3,244.86 million and a net loss of US$70.79 million, driven in part by a US$127.99 million goodwill impairment, while also outlining 2026 revenue guidance of US$3.44 billion to US$3.51 billion.
• Alongside these results, management highlighted record patient volumes, the launch of a large capitated contract, and fresh home medical equipment acquisitions funded partly by a US$100 million revolver draw, signalling an ongoing shift toward scale, value-based care, and portfolio focus.
• Next, we’ll examine how the goodwill impairment and heavier upfront spending for the new capitated contract could reshape AdaptHealth’s investment narrative.

Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

AdaptHealth Investment Narrative Recap

To own AdaptHealth today, you need to believe that its scale in home medical equipment and the new US$1+ billion capitated contract can offset regulatory pressures and recent earnings volatility. The latest results, including a US$127.99 million goodwill impairment and upfront spending to stand up the capitated deal, sharpen the near term focus on execution risk around this contract, while CMS reimbursement decisions still look like the biggest external swing factor.

The most relevant recent development here is management’s 2026 outlook, calling for US$3.44 billion to US$3.51 billion in net revenue alongside record patient volumes and early spending to support the capitated contract. When you put that next to the fresh acquisitions funded with a US$100 million revolver draw, it reinforces that the key catalyst remains how smoothly AdaptHealth converts its expanded footprint and value based arrangements into durable, profitable revenue.

Yet behind that growth story, investors should also be aware of how cost overruns on the new capitated contract could...

AdaptHealth's narrative projects $4.0 billion revenue and $157.7 million earnings by 2028. This requires 7.6% yearly revenue growth and a $83.9 million earnings increase from $73.8 million today.

Uncover how AdaptHealth's forecasts yield a $13.12 fair value, a 45% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming only about 5.3% annual revenue growth to roughly US$3.8 billion and earnings near US$168 million by 2028, and this new impairment plus heavier upfront contract costs may reinforce their view that margins stay under pressure, so it is worth weighing their more pessimistic take alongside the more optimistic consensus before you decide what story you believe.

Explore 3 other fair value estimates on AdaptHealth - why the stock might be worth over 3x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AdaptHealth research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free AdaptHealth research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AdaptHealth's overall financial health at a glance.

Interested In Other Possibilities?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 23 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.